During the AD/PD™ (Alzheimer’s and Parkinson’s disease) Conference in March 2026, a consistent theme emerged across scientific and industry discussions: while progress in understanding neurodegenerative diseases (NDDs) has accelerated, the field is converging on the view that these diseases are biologically heterogeneous, with different progression trajectories, symptomatology and lived experiences. Despite significant scientific progress and unprecedented industry investment, advances in NDD research continue to reveal a level of complexity that cannot be addressed by single or homogenous treatment approaches.
Back
Strategy Consulting